Biodexa Pharmaceuticals (BDRX) Share-based Compensation (2019 - 2021)
Biodexa Pharmaceuticals (BDRX) posted Share-based Compensation of $51410.9 for Q3 2021, up 108.23% sequentially from -$624573.3 in Q4 2020, and up 108.63% YoY from $24642.0 in Q3 2020.
Biodexa Pharmaceuticals (BDRX) Share-based Compensation (2019 - 2021) Analysis & Trends
Biodexa Pharmaceuticals has reported Share-based Compensation for 3 years, with the latest figure at $51410.9 in Q3 2021.
- Quarterly Share-based Compensation rose 108.63% year-over-year to $51410.9 in Q3 2021, while the trailing twelve-month figure through Sep 2021 was -$1.1 million (changed N/A YoY) and the FY2025 annual result came in at $224146.8, down 38.29% from the prior year.
- Share-based Compensation climbed to $51410.9 in Q3 2021 per BDRX's latest filing, from -$624573.3 in the prior quarter.
- Over five years, Share-based Compensation peaked at $51410.9 in Q3 2021 and troughed at -$624573.3 in Q4 2020.
- A 3-year average of -$245083.0 and a median of -$90041.9 in 2019 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2020 and 2021: Share-based Compensation slumped 1968.37% in 2020, then jumped 108.63% in 2021.
- Over 3 years, Share-based Compensation stood at $33428.8 in 2019, then plunged by 1968.37% to -$624573.3 in 2020, then surged by 108.23% to $51410.9 in 2021.
- According to Business Quant data, Share-based Compensation over the past three periods registered $51410.9, -$624573.3, and -$595639.6 for Q3 2021, Q4 2020, and Q3 2020 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.61 Bn | 131.75 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.28 Bn | 60.09 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.14 Bn | 54.00 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.13 Bn | 37.03 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.83 Bn | 28.52 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | - |
| 10 | Biodexa Pharmaceuticals | 65,093.53 | -11.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 17, 2021 | 51,410.94 |
| Sep 17, 2021 | 51,410.94 |
| Dec 31, 2020 | -624,573.32 |
| Dec 31, 2020 | -624,573.32 |
| Sep 10, 2020 | -595,639.61 |
| Sep 10, 2020 | -595,639.61 |
| Dec 31, 2019 | 33,428.85 |
| Dec 31, 2019 | 33,428.85 |
| Jun 30, 2019 | -90,041.88 |
| Jun 30, 2019 | -90,041.88 |